Skip to Content
Merck
All Photos(1)

Key Documents

Y0000469

Beclometasone dipropionate for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Beclomethasone dipropionate, 9-Chloro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C28H37ClO7
CAS Number:
Molecular Weight:
521.04
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

beclometasone

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C

InChI

1S/C28H37ClO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1

InChI key

KUVIULQEHSCUHY-XYWKZLDCSA-N

Gene Information

human ... NR3C1(2908)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Beclometasone dipropionate for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard

Signal Word

Warning

Hazard Statements

Hazard Classifications

Repr. 2 - STOT RE 2

Target Organs

Adrenal gland,Immune system,Bone

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

T B Edwards
Clinical therapeutics, 17(6), 1032-1041 (1995-11-01)
There is an increasing trend toward topical intranasal corticosteroids as the preferred treatment for seasonal or perennial allergic rhinitis. This trend is based on the fact that the chronic, mucosal inflammation that accompanies allergic rhinitis responds to anti-inflammatory drugs such
Effect of inhaled beclomethasone dipropionate and budesonide on adrenal function, skin changes and cataract formation.
R G Dluhy
Respiratory medicine, 92 Suppl B, 15-23 (1999-04-08)
J C Guérin et al.
Presse medicale (Paris, France : 1983), 21(32), 1526-1531 (1992-10-03)
Beclomethasone dipropionate has now been used for more than 10 years during which our knowledge of how to use inhaled corticosteroids has gradually improved: high dose initial treatment followed by progressive reduction down to the minimum effective dosage; administration in
George B McDonald
Expert opinion on investigational drugs, 16(10), 1709-1724 (2007-10-10)
Beclomethasone dipropionate (BDP) is a topically active anti-inflammatory corticosteroid. Oral BDP is metabolized in the intestine to a potent metabolite, 17-beclomethasone monopropionate (17-BMP). An oral formulation (orBec; DOR BioPharma), consisting of a gastric release and an enteric-coated pill, was studied
P Chervinsky
Clinical therapeutics, 18(5), 790-796 (1996-09-01)
A new double-strength (84 micrograms/spray) formulation of beclomethasone dipropionate (BDP-ds) as an aqueous suspension has been introduced to control symptoms of allergic rhinitis with once-daily intranasal dosing. This paper reviews the results of three clinical reports which show that BDP-ds

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service